Anti-MDA5 antibody-positive dermatomyositis frequently leads to rapidly progressive-interstitial lung diseases (RP-ILD), a condition with poor prognosis despite standard therapy [1]. This evidence concerns the gene IFIH1 and interstitial lung disease.